Riociguat
(Difference between revisions)
Ossip Groth (Talk | contribs) m |
Ossip Groth (Talk | contribs) m |
||
| Line 5: | Line 5: | ||
{{tp|p=23883378|t=2013. Riociguat for the treatment of pulmonary arterial hypertension |pdf=http://www.nejm.org/doi/pdf/10.1056/NEJMoa1209655|usr=}} | {{tp|p=23883378|t=2013. Riociguat for the treatment of pulmonary arterial hypertension |pdf=http://www.nejm.org/doi/pdf/10.1056/NEJMoa1209655|usr=}} | ||
{{tp|p=23883377|t=2013. Riociguat for the treatment of chronic thromboembolic pulmonary hypertension |pdf=http://www.nejm.org/doi/pdf/10.1056/NEJMoa1209657|usr=}} | {{tp|p=23883377|t=2013. Riociguat for the treatment of chronic thromboembolic pulmonary hypertension |pdf=http://www.nejm.org/doi/pdf/10.1056/NEJMoa1209657|usr=}} | ||
| + | {{tp|p=20530034|t=2010. Riociguat for chronic thromboembolic pulmonary hypertension and pulmonary arterial hypertension: a phase II study |pdf=http://erj.ersjournals.com/content/erj/36/4/792.full.pdf|usr=}} | ||
| Line 19: | Line 20: | ||
{{tp|p=25309604|t=2014. Respiratory review of 2014: pulmonary thromboembolism |pdf=http://www.e-trd.org/upload/abstract/files/v77n03105.pdf|usr=}} | {{tp|p=25309604|t=2014. Respiratory review of 2014: pulmonary thromboembolism |pdf=http://www.e-trd.org/upload/abstract/files/v77n03105.pdf|usr=}} | ||
{{tp|p=24401129|t=2014. Novel and emerging therapies for pulmonary hypertension |pdf=http://www.atsjournals.org/doi/pdf/10.1164/rccm.201308-1543PP|usr=}} | {{tp|p=24401129|t=2014. Novel and emerging therapies for pulmonary hypertension |pdf=http://www.atsjournals.org/doi/pdf/10.1164/rccm.201308-1543PP|usr=}} | ||
| + | {{tp|p=23397304|t=2013. Chronic thromboembolic pulmonary hypertension: role of medical therapy |pdf=http://erj.ersjournals.com/content/erj/41/4/985.full.pdf|usr=}} | ||
==Mechanism of action== | ==Mechanism of action== | ||
| Line 31: | Line 33: | ||
==Some trials== | ==Some trials== | ||
| − | + | {{tp|p=24991733|t=2014. Acute hemodynamic effects of riociguat in patients with pulmonary hypertension associated with diastolic heart failure (DILATE-1): a randomized, double-blind, placebo-controlled, single-dose study |pdf=http://sm.kidney.de/epmc.php?ep=eu&pmid=24991733&pmc=4219342&ti=Acute%20hemodynamic%20effects%20of%20riociguat%20in%20patients%20with%20pulmonary%20hypertension%20associated%20with%20diastolic%20heart%20failure%20%28DILATE-1%29:%20a%20randomized,%20double-blind,%20placebo-controlled,%20single-dose%20study|usr=}} | |
{{tp|p=24738736|t=2014. Stimulation of soluble guanylate cyclase prevents cigarette smoke-induced pulmonary hypertension and emphysema |pdf=http://www.atsjournals.org/doi/pdf/10.1164/rccm.201311-2037OC|usr=}} | {{tp|p=24738736|t=2014. Stimulation of soluble guanylate cyclase prevents cigarette smoke-induced pulmonary hypertension and emphysema |pdf=http://www.atsjournals.org/doi/pdf/10.1164/rccm.201311-2037OC|usr=}} | ||
{{tp|p=26064454|t=2015. Acute effects of riociguat in borderline or manifest pulmonary hypertension associated with chronic obstructive pulmonary disease |pdf=http://www.jstor.org/stable/pdfplus/10.1086/680214.pdf?acceptTC=true&jpdConfirm=true|usr=}} | {{tp|p=26064454|t=2015. Acute effects of riociguat in borderline or manifest pulmonary hypertension associated with chronic obstructive pulmonary disease |pdf=http://www.jstor.org/stable/pdfplus/10.1086/680214.pdf?acceptTC=true&jpdConfirm=true|usr=}} | ||
{{tp|p=26011408|t=2015. Change of right heart size and function by long-term therapy with riociguat in patients with pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension |pdf=http://www.internationaljournalofcardiology.com/article/S0167-5273(15)01168-7/pdf|usr=}} | {{tp|p=26011408|t=2015. Change of right heart size and function by long-term therapy with riociguat in patients with pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension |pdf=http://www.internationaljournalofcardiology.com/article/S0167-5273(15)01168-7/pdf|usr=}} | ||
| + | {{tp|p=23775259|t=2013. Treatment of pulmonary hypertension caused by left heart failure with pulmonary arterial hypertension-specific therapies: lessons from the right and LEPHT |pdf=http://circ.ahajournals.org/content/128/5/475.full.pdf|usr=}} | ||
| + | {{tp|p=23775260|t=2013. Riociguat for patients with pulmonary hypertension caused by systolic left ventricular dysfunction: a phase IIb double-blind, randomized, placebo-controlled, dose-ranging hemodynamic study |pdf=http://circ.ahajournals.org/content/128/5/502.full.pdf|usr=}} | ||
==Nephrology-related data== | ==Nephrology-related data== | ||
| + | {{tp|p=25645316|t=2015. Renal effects of soluble guanylate cyclase stimulators and activators: a review of the preclinical evidence |pdf=http://www.sciencedirect.com/science/article/pii/S1471489214001817|usr=}} | ||
{{tp|p=21789188|t=2011. Soluble guanylate cyclase stimulation prevents fibrotic tissue remodeling and improves survival in salt-sensitive Dahl rats |pdf=http://sm.kidney.de/epmc.php?ep=eu&pmid=21789188&pmc=3138745&ti=Soluble%20guanylate%20cyclase%20stimulation%20prevents%20fibrotic%20tissue%20remodeling%20and%20improves%20survival%20in%20salt-sensitive%20Dahl%20rats%20|usr=}} | {{tp|p=21789188|t=2011. Soluble guanylate cyclase stimulation prevents fibrotic tissue remodeling and improves survival in salt-sensitive Dahl rats |pdf=http://sm.kidney.de/epmc.php?ep=eu&pmid=21789188&pmc=3138745&ti=Soluble%20guanylate%20cyclase%20stimulation%20prevents%20fibrotic%20tissue%20remodeling%20and%20improves%20survival%20in%20salt-sensitive%20Dahl%20rats%20|usr=}} | ||
==Books== | ==Books== | ||
Revision as of 14:56, 26 October 2015
Contents |
Core OA papers on Riociguat
| Journal article, free access |
| GET 2014. Riociguat (adempas): a novel agent for the treatment of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension Extract PDF direct |
| Journal article, free access |
| GET 2015. Riociguat: Something new in pulmonary hypertension therapeutics? Extract PDF direct |
| Journal article, free access |
| GET 2014. Riociguat (adempas): a novel agent for the treatment of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension Extract PDF direct |
| Journal article, free access |
| GET 2013. Riociguat for the treatment of pulmonary arterial hypertension Extract PDF direct |
| Journal article, free access |
| GET 2013. Riociguat for the treatment of chronic thromboembolic pulmonary hypertension Extract PDF direct |
| Journal article, free access |
| GET 2010. Riociguat for chronic thromboembolic pulmonary hypertension and pulmonary arterial hypertension: a phase II study Extract PDF direct |
General outline of Pulmonary Hypertension
| Journal article, free access |
| GET 2013. Recent progress in the diagnosis and management of chronic thromboembolic pulmonary hypertension Extract PDF direct |
| Journal article, free access |
| GET 2015. Medical treatment update on pulmonary arterial hypertension Extract PDF direct |
| Journal article, free access |
| GET 2015. The molecular targets of approved treatments for pulmonary arterial hypertension Extract PDF direct |
| Journal article, free access |
| GET 2015. Pharmacological therapy for patients with chronic thromboembolic pulmonary hypertension Extract PDF direct |
| Journal article, free access |
| GET 2014. Drug Therapy for Chronic Thromboembolic Pulmonary Hypertension: A Review of the Comparative Clinical Effectiveness Extract PDF direct |
| Journal article, free access |
| GET 2014. Saudi Guidelines on the Diagnosis and Treatment of Pulmonary Hypertension: Chronic thromboembolic pulmonary hypertension Extract PDF direct |
| Journal article, free access |
| GET 2014. Saudi Guidelines on the Diagnosis and Treatment of Pulmonary Hypertension: Medical and surgical management for pulmonary arterial hypertension Extract PDF direct |
| Journal article, free access |
| GET 2013. Therapies for pulmonary arterial hypertension: where are we today, where do we go tomorrow? Extract PDF direct |
| Journal article, free access |
| GET 2014. Respiratory review of 2014: pulmonary thromboembolism Extract PDF direct |
| Journal article, free access |
| GET 2014. Novel and emerging therapies for pulmonary hypertension Extract PDF direct |
| Journal article, free access |
| GET 2013. Chronic thromboembolic pulmonary hypertension: role of medical therapy Extract PDF direct |
Mechanism of action
| Journal article, free access |
| GET 2010. Riociguat: an upcoming therapy in chronic thromboembolic pulmonary hypertension? Extract PDF direct |
| Journal article, free access |
| GET 2009. Soluble guanylate cyclase stimulation: an emerging option in pulmonary hypertension therapy Extract PDF direct |
| Journal article, free access |
| GET 2008. Expression and function of soluble guanylate cyclase in pulmonary arterial hypertension Extract PDF direct |
Some trials
| Journal article, free access |
| GET 2014. Acute hemodynamic effects of riociguat in patients with pulmonary hypertension associated with diastolic heart failure (DILATE-1): a randomized, double-blind, placebo-controlled, single-dose study Extract PDF direct |
| Journal article, free access |
| GET 2014. Stimulation of soluble guanylate cyclase prevents cigarette smoke-induced pulmonary hypertension and emphysema Extract PDF direct |
| Journal article, free access |
| GET 2015. Acute effects of riociguat in borderline or manifest pulmonary hypertension associated with chronic obstructive pulmonary disease Extract PDF direct |
| Journal article, free access |
| GET 2015. Change of right heart size and function by long-term therapy with riociguat in patients with pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension Extract PDF direct |
| Journal article, free access |
| GET 2013. Treatment of pulmonary hypertension caused by left heart failure with pulmonary arterial hypertension-specific therapies: lessons from the right and LEPHT Extract PDF direct |
| Journal article, free access |
| GET 2013. Riociguat for patients with pulmonary hypertension caused by systolic left ventricular dysfunction: a phase IIb double-blind, randomized, placebo-controlled, dose-ranging hemodynamic study Extract PDF direct |
| Journal article, free access |
| GET 2015. Renal effects of soluble guanylate cyclase stimulators and activators: a review of the preclinical evidence Extract PDF direct |
| Journal article, free access |
| GET 2011. Soluble guanylate cyclase stimulation prevents fibrotic tissue remodeling and improves survival in salt-sensitive Dahl rats Extract PDF direct |
Books
